Zentalis Q4 2023 Earnings Report
Key Takeaways
Zentalis Pharmaceuticals reported a cash balance of $483 million as of December 31, 2023, projecting a cash runway into 2026. The company is advancing its azenosertib clinical development program and anticipates multiple clinical data readouts in 2024 and 2025, with plans to submit its first NDA in 2026. They also strengthened their management team with key appointments.
Azenosertib clinical development plan is ongoing and on track, with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer types during 2024.
Diana Hausman, M.D., was appointed as Chief Medical Officer, and Kyle Rasbach, Ph.D., Pharm.D., as Chief Business Officer, strengthening the management team.
Cash balance was $483 million as of December 31, 2023, with projected cash runway into 2026.
In November 2023, promising clinical data was disclosed demonstrating the potential of azenosertib as an effective monotherapy in ovarian cancer and uterine serous carcinoma.